Healthcare & Life Sciences

Myrtelle

United States
alive
Sign in to unlock

About

Myrtelle develops gene therapies that target oligodendrocytes to treat myelin disorders and neurodegenerative diseases, with a lead candidate for Canavan's disease that has received FDA Orphan Drug, Rare Pediatric Disease, and Fast Track designations.

Explore Myrtelle's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.

Sign in to unlockView pricing